American Century多部门浮动收益主动型ETF FUSI 深 沪
交易中 04-01 10:44:48 美东时间
50.3899
+0.018
+0.04%
华盛通- 最 高50.395
- 今 开50.395
- 成交量 1474股
- 最 低 50.3899
- 昨 收 50.3716
- 总市值 2267.55万
- 52周最高 50.40
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 47.6777
- 委 比 -33.33%
- 总股本 45.00万
- 历史最高 50.395
- 量 比 5.07
- 振 幅 0.01%
- 历史最低 41.4229
- 每 手 1
- 风险率 0.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Nvidia Ai Ecosystem Expands As Marvell Joins Forces Through Nvlink Fusion
BRIEF-Nvidia Ai Ecosystem Expands As Marvell Joins Forces Through Nvlink Fusion March 31 (Reuters) - NVIDIA Corp NVDA.O : NVIDIA AI ECOSYSTEM EXPANDS AS MARVELL JOINS FORCES THROUGH NVLINK FUSION NVIDIA CORP - INVESTS $2 BILLION IN MARVELL NVIDIA CORP - CO AND MARVELL TO COLLABORATE ON SILICON PHOTO
03-31 20:30
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval March 27 (Reuters) - Sanofi SA SASY.PA : SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION ADMINISTERED VIA ON-BODY INJECTOR RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT MULTIPLE MYELOMA IF APPROVED, SARCL
03-27 20:03
BRIEF-Fusion Fuel Approves Appointment Of Uranium Investor James Passin To Board As Company Undertakes Uranium Royalty Strategy
BRIEF-Fusion Fuel Approves Appointment Of Uranium Investor James Passin To Board As Company Undertakes Uranium Royalty Strategy Fusion Fuel Green PLC HTOO.O : FUSION FUEL APPROVES APPOINTMENT OF URANIUM INVESTOR JAMES PASSIN TO BOARD AS COMPANY UNDERTAKES URANIUM ROYALTY STRATEGY Source text: ID:nGN
03-23 20:12
BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic
BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic March 17 (Reuters) - HCW Biologics Inc HCWB.O : HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC HCW BIOLOGICS INC - RECEIVES $7.
03-17 19:51
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
03-14 23:51
BRIEF-Sumitomo Corp - Investment In U.S.-Based Fusion Company Shine Technologies
BRIEF-Sumitomo Corp - Investment In U.S.-Based Fusion Company Shine Technologies March 10 (Reuters) - Sumitomo Corp 8053.T : SUMITOMO CORP - INVESTMENT IN U.S.-BASED FUSION COMPANY SHINE TECHNOLOGIES Source text: [ID:] Further company coverage: 8053.T
03-10 09:04
BRIEF-Zoox Launching Operations In Arizona, Beginning With Phoenix, Expanding Testing In Texas To Dallas
BRIEF-Zoox Launching Operations In Arizona, Beginning With Phoenix, Expanding Testing In Texas To Dallas March 9 (Reuters) - Amazon.com Inc AMZN.O : ZOOX: OPENING THIRD ZOOX FUSION CENTER FACILITY IN SCOTTSDALE, ARIZONA ZOOX: LAUNCHING OPERATIONS IN ARIZONA, BEGINNING WITH PHOENIX, EXPANDING TESTING
03-09 21:00
Fusion Finance seeks SEBI-compliant reclassification of promoter holdings as public
Fusion Finance Ltd ( ($IN:FUSION) ) has shared an update. Fusion Finance Limite...
03-03 00:45
ConvaTec prelim 2025 revenue slightly beats on Infusion Care unit strength
ConvaTec prelim 2025 revenue slightly beats on Infusion Care unit strength Overview Medical products firm's 2025 revenue slightly beat analyst expectations, growing 6.5% yr/yr 2025 EBIT missed analyst estimates, declining compared to previous year Company announced $300 mln share buyback and increas
02-24 15:10
Fusion Finance Promoter Group Seeks Reclassification as Public Shareholders
Fusion Finance Ltd ( ($IN:FUSION) ) just unveiled an update. Fusion Finance Ltd...
02-21 23:48
